Antibody, Drugs, In-Vitro and RNA - Clinical Research Informer

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. OR: The presentations at ESMO TAT 2024 highlighted our advances in targeted and more personalised anti-tumour therapies. We were there to present the latest findings from our research.

RNA

RNA In-Vivo In-Vitro DNA

Multispecific antibody shows promise in B cell lymphoma

Drug Discovery World

JUNE 17, 2024

A multispecific antibody candidate for B cell lymphoma preferentially engaged CD47 in presence of co-engagement of CD20 and CD19, in preclinical investigations. Monoclonal antibody immunotherapies can provide an effective treatment for B cell lymphoma.

Antibody

Antibody In-Vivo In-Vitro Engineer

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

AUGUST 3, 2022

Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake.

Bioavailability

Bioavailability In-Vivo RNA In-Vitro

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

The Pharma Data

SEPTEMBER 1, 2020

Food and Drug Administration (FDA). with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions.

In-Vitro

In-Vitro Antibody Medicine Clinical Trials

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

The Pharma Data

NOVEMBER 29, 2021

First Combination of Immunotherapy With Tyrosine Kinase Inhibitor Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation.

In-Vitro

In-Vitro Containment Development Medicine

RNA Therapeutics: A Novel Approach to Treating Diseases

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA

RNA Protein Genetics Gene Expression

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. All drug development processes evaluate a drug’s pharmacokinetics (PK) to gather data about its absorption, distribution, metabolism, and excretion in the body.

Clinical Trials

Clinical Trials Clinical Trials Trials Antibody

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. These tumor-derived entities are used to derive genomic and proteomic data. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials

Clinical Trials Clinical Trials Trials FDA Approval

Organ-on-a-chip models in drug development

Drug Discovery World

APRIL 12, 2023

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development

Development In-Vivo Drugs In-Vitro

Organ-on-a-chip models in drug development

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by CN Bio appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Development

Development In-Vivo Drugs In-Vitro

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS

The Pharma Data

AUGUST 31, 2020

Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S.

FDA Approval

FDA Approval In-Vitro Antibody Medicine

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems

The Pharma Data

SEPTEMBER 3, 2020

Food and Drug Administration (FDA). Test for use on high-throughput cobas 6800/8800 Systems will continue to support high volume testing . This test is also available in markets accepting the CE mark. Additionally, it is available in markets accepting the CE mark. Multiplexing will increase lab efficiency and save resources in the labs.

In-Vitro

In-Vitro Antibody Medicine Clinical Trials

New HCV Test Enables Diagnosis and Treatment in a Single Visit

XTalks

JULY 10, 2024

The US Food and Drug Administration (FDA) has granted marketing authorization to Cepheid for its groundbreaking Xpert HCV test and GeneXpert Xpress System, marking a significant advancement in the diagnosis and treatment of hepatitis C virus (HCV).

RNA

RNA In-Vitro Genotype Marketing

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. The price of that prize is incalculable.

Vaccination

Vaccination Vaccine Antibody Life Science

Clinical Research Informer

Conversations from ESMO Targeted Anticancer Therapies Congress 2024

Multispecific antibody shows promise in B cell lymphoma

Trending Sources

Cell-penetrating peptides as a delivery system for oligonucleotides

Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of care

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

RNA Therapeutics: A Novel Approach to Treating Diseases

Receptor Occupancy Assays by Flow Cytometry: Benefits for Clinical Trials

The Utility of Liquid Biopsy in Oncology Clinical Trials

Organ-on-a-chip models in drug development

Organ-on-a-chip models in drug development

Roche receives FDA approval for first HIV-1/HIV-2 Qualitative Test on the cobas 6800/8800 Systems in the fight against HIV/AIDS

Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems

New HCV Test Enables Diagnosis and Treatment in a Single Visit

COVID-19 Pandemic Coverage

Stay Connected